A Study of Buntanetap in Participants With PD
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Annovis Bio Inc.
- Study ID
- NCT07284784
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Deep Brain Stimulation
- Parkinson's Disease (PD)
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- buntanetap/posiphen — DRUGbuntanetap capsules 30 mg by mouth daily
Study Details
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Key Dates
- Start date
- Jan 9, 2026
- Status verified
- Jun 2026
- Primary completion
- Sep 30, 2029
- Completion
- Nov 30, 2029
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1 - buntanetapCohort 1 will enroll via invitation only for PD participants who have previously participated in bun
- Experimental: Cohort 2 - buntanetapCohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.
Primary Outcome Measure
Safety of buntanetap [ Time Frame: 36-months of treatment ]
Central Contacts
- Sarah MacCallum, BSN RN484-875-3192
- Alexander Morin, PhD
Locations (27)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Natividad Stover, M.D. (PRINCIPAL_INVESTIGATOR) |
| Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research | Sun City | Arizona | 85351 | Sara Dhanani, M.D. (PRINCIPAL_INVESTIGATOR) |
| Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office | Fountain Valley | California | 92708 | Daniel Truong, M.D. (PRINCIPAL_INVESTIGATOR) |
| Cenexel Rocky Mountain Clinical Research | Englewood | Colorado | 80113 | Meagen Salinas, M.D. (PRINCIPAL_INVESTIGATOR) |
| New England Institute for Clinical Research (Ki Health Partners) | Stamford | Connecticut | 06824 | Peter McAllister, M.D. (PRINCIPAL_INVESTIGATOR) |
| First Choice Neurology - Aventura Neurologic Associates | Aventura | Florida | 33180 | Jonathan Cross, M.D. (PRINCIPAL_INVESTIGATOR) |
| Arrow Clinical Trials | Daytona Beach | Florida | 32117 | David Billmeier, M.D. (PRINCIPAL_INVESTIGATOR) |
| Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU | DeLand | Florida | 32720 | Bruce Rankin, D.O. (PRINCIPAL_INVESTIGATOR) |
| Renstar Medical Research | Ocala | Florida | 34470 | Annette Nieves, M.D. (PRINCIPAL_INVESTIGATOR) |
| University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di | Tampa | Florida | 33613 | Robert Hauser, M.D., MBA (PRINCIPAL_INVESTIGATOR) |
| Conquest Research | Winter Park | Florida | 32789 | Rekha Gandhi, M.D. (PRINCIPAL_INVESTIGATOR) |
| iResearch Atlanta | Decatur | Georgia | 30030 | Kimball Johnson, M.D. (PRINCIPAL_INVESTIGATOR) |
| Josephson Wallack Munshower Neurology, P.C. | Indianapolis | Indiana | 46256 | Kristi George, M.D. (PRINCIPAL_INVESTIGATOR) |
| University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D | Kansas City | Kansas | 66160 | Rajesh Pahwa, M.D. (PRINCIPAL_INVESTIGATOR) |
| Quest Research Institute | Farmington Hills | Michigan | 48334 | Aaron Ellenbogen, D.O. (PRINCIPAL_INVESTIGATOR) |
| Mount Sinai Hospital | New York | New York | 10019 | Joohi Jimenez-Shahed, M.D. (PRINCIPAL_INVESTIGATOR) |
| Duke Department of Neurosurgery | Durham | North Carolina | 27710 | Kyle Mitchell, M.D. (PRINCIPAL_INVESTIGATOR) |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | Zachary Jordan, M.D. (PRINCIPAL_INVESTIGATOR) |
| The Movement Disorder Clinic of Oklahoma | Tulsa | Oklahoma | 74136 | Kevin Klos, M.D. (PRINCIPAL_INVESTIGATOR) |
| Abington Neurology | Willow Grove | Pennsylvania | 19090 | David Weisman, M.D. (PRINCIPAL_INVESTIGATOR) |
| Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease | Charleston | South Carolina | 29401 | Vanessa Hinson, M.D., PhD (PRINCIPAL_INVESTIGATOR) |
| Neurology Clinic, P.C. | Cordova | Tennessee | 38018 | Kendrick Henderson, M.D. (PRINCIPAL_INVESTIGATOR) |
| Veracity Neuroscience LLC | Memphis | Tennessee | 38157 | Mark LeDoux, M.D., PhD (PRINCIPAL_INVESTIGATOR) |
| Central Texas Neurology | Round Rock | Texas | 78681 | Elizabeth Peckham, M.D. (PRINCIPAL_INVESTIGATOR) |
| University of Virginia Health System (UVAHS) - Adult Neurology Clinic | Charlottesville | Virginia | 22903 | Binit Shah, M.D. (PRINCIPAL_INVESTIGATOR) |
| Inland Northwest Research | Spokane | Washington | 99202 | Jason Aldred, M.D. (PRINCIPAL_INVESTIGATOR) |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Karen Blindauer, M.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham· Birmingham, ALBanner Sun Health Research Institute - Cleo Roberts Center for Clinical Research· Sun City, AZParkinson's & Movement Disorder Institute (PMDI) - Orange County Office· Fountain Valley, CACenexel Rocky Mountain Clinical Research· Englewood, CONew England Institute for Clinical Research (Ki Health Partners)· Stamford, CTFirst Choice Neurology - Aventura Neurologic Associates· Aventura, FL
Related Studies
- Understanding Motivation in Parkinson's Patients Through NeurophysiologyRecruiting · University of California, San Francisco · San Francisco, California
- Use of CereGate Therapy for Freezing of Gait in PDRecruiting · CereGate Inc. · Redwood City, California
- Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's DiseaseRecruiting · University of California, Los Angeles · Los Angeles, California
- Imaging Biomarkers of FOG Response to DBSPHASE4 · Recruiting · Medical University of South Carolina · Charleston, South Carolina